Clinical Trial Update: Study to Assess Safety/Tolerability/Efficacy of Gefitinib Versus Docetaxel in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [Phase 4]

View source ↗

Summary

A Phase 4 trial comparing gefitinib vs. docetaxel in locally advanced or metastatic non-small cell lung cancer was terminated, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Iressa (gefitinib)
• Taxotere (docetaxel)

Snippet

Sponsor: AstraZeneca | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 4 | Status: TERMINATED | Results posted: 2013-10-01